Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering AG Makes Oncology A Primary Focus; Dermatology No Longer “Core”

Executive Summary

Schering AG is establishing a new global oncology business unit that will be headquartered in the U.S

You may also be interested in...



Schering AG dermatology business “Intendis”

Schering AG names separate dermatology business group Intendis. Company will formally begin operations Jan. 1. U.S. headquarters in Montville, N.J. will house about 70 out of approximately 600 global Intendis employees. Managing Director Wolfgang Kehr will lead global headquarters in Berlin. U.S. management will include North & Latin America Marketing & Sales head Bernhard Schefter. Schering announced in June it was spinning off "non-core" businesses to focus on oncology (1"The Pink Sheet" June 21, 2004, p. 38)....

Schering AG dermatology business “Intendis”

Schering AG names separate dermatology business group Intendis. Company will formally begin operations Jan. 1. U.S. headquarters in Montville, N.J. will house about 70 out of approximately 600 global Intendis employees. Managing Director Wolfgang Kehr will lead global headquarters in Berlin. U.S. management will include North & Latin America Marketing & Sales head Bernhard Schefter. Schering announced in June it was spinning off "non-core" businesses to focus on oncology (1"The Pink Sheet" June 21, 2004, p. 38)....

Berlex To Submit Angeliq NDA Response In March, Add Cardioprotective Data

Schering AG's Berlex subsidiary expects to complete its response to FDA on its NDA for the hormone replacement therapy Angeliq in March

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel